HZRM

Hangzhou Ruiming Biotechnology (HZRM) is a Chinese biotechnology company specializing in the development and commercialization of liquid biopsy technologies for cancer diagnostics. The company's core business revolves around its proprietary platform for the enrichment and detection of circulating tumor cells (CTCs) from peripheral blood. HZRM provides clinical-grade diagnostic solutions for early cancer screening, treatment monitoring, and prognosis assessment across various solid tumors, including lung and breast cancers. By leveraging advanced microfluidic and immunomagnetic bead technologies, the company aims to provide non-invasive alternatives to traditional tissue biopsies.